Expert Opinion on Drug Safety
April 15, 2022
Giordano Novak Rossi, Jaime E. C. Hallak, José Carlos Bouso Saiz et al.
24 citations
In the reviewed studies, no serious adverse events were linked to psilocybin or LSD administration. Most side effects were anticipated, manageable, and temporary. However, concerns persist about certain effects like dissociation, paranoia, and confusion. The authors conclude that larger randomized controlled trials are needed to confirm therapeutic benefits and further assess safety and tolerability.
Front Psychiatry
November 6, 2024
Cristiano Chaves, Rafael G. Dos Santos, Serdar M. Dursun et al.
11 citations
DMT (N,N-dimethyltryptamine) is a naturally occurring psychedelic found in plants and produced endogenously in the human body. Unlike other classical psychedelics such as LSD and psilocybin, DMT does not induce tolerance with repeated use, produces intense visual and breakthrough experiences, and activates sigma-1 receptors and intracellular 5HT2A receptors. Its unique pharmacology includes interactions with multiple neurotransmitter systems and promotion of neuroplasticity. Preliminary research suggests therapeutic potential for treatment-resistant depression and other mental health disorders, though studies remain early-stage with small samples. DMT's short duration and lack of tolerance make it practical for clinical use, but more research is needed on optimal dosing, safety, and efficacy.
Therapeutic Drug Monitoring
January 9, 2014
Rafael G. Dos Santos
5 citations
No Summary
Anesthesiology
May 21, 2014
Rafael G. Dos Santos
1 citation
A commentary critiques a prior article on psychedelic research, arguing it underrepresents the role of glutamate in psychedelic neurochemistry and incorrectly claims that psilocybin is the only classic psychedelic studied with human neuroimaging. The commentary notes that head-twitch behavior, a mouse proxy for human psychedelic action, depends on metabotropic glutamate 2 receptors co-expressed with 5-HT2A receptors. It also lists human neuroimaging studies of mescaline, dimethyltryptamine, and ayahuasca. The commentary raises unresolved questions about discrepancies between intravenous psilocybin studies showing decreased cerebral blood flow and oral psilocybin studies showing increased glucose metabolism.
Prog Neuropsychopharmacol Biol Psychiatry
October 20, 2025
Arthur L. De Oliveira, Danielle P. De Oliveira, Rafael G. Dos Santos et al.
A systematic review of 13 studies examined the developmental toxicity and behavioral effects of psychedelics in zebrafish. Substances included ayahuasca, DMT, ibogaine, LSD, MDMA, mescaline, noribogaine, psilocybin, and psilocin. Overall, psychedelics did not cause morphological abnormalities in embryo-larvae, though ayahuasca induced edemas and increased mortality at high concentrations. Ibogaine, MDMA, and LSD were linked to locomotor impairments after developmental exposure. DMT, psilocybin, and psilocin had anxiolytic effects on larvae, while LSD, MDMA, mescaline, and noribogaine reduced anxiety in adult fish. The findings suggest a safe toxicological profile at low concentrations, but whether they cause neurodevelopmental deficits in offspring remains unclear.
Braz J Psychiatry
September 29, 2025
José Augusto S. Reis, Giordano N. Rossi, Anna Beatriz V. Zacharias et al.
A case report describes an instance of acute suicidal behavior that occurred after a participant ingested ayahuasca in a clinical trial setting. The report details the circumstances and clinical presentation of this adverse event, highlighting a potential risk associated with ayahuasca use even within a controlled research environment. The authors suggest that such reactions, though rare, warrant careful screening and monitoring of participants in psychedelic research.